Ptc Therapeutics (PTCT) Preferred Stock Liabilities (2012)

Ptc Therapeutics (PTCT) recorded quarterly Preferred Stock Liabilities of $80.8 million in Q4 2012.

Ptc Therapeutics (PTCT) Preferred Stock Liabilities (2012) Analysis & Trends

Ptc Therapeutics' Preferred Stock Liabilities history runs 1 years deep, the most recent figure standing at $80.8 million for Q4 2012.

In Q4 2012, Preferred Stock Liabilities changed N/A year-over-year to $80.8 million; the TTM figure through Dec 2012 stood at $80.8 million (changed N/A YoY), while the FY2012 annual figure was $80.8 million, down 62.3% from the prior year.
Preferred Stock Liabilities was $80.8 million for Q4 2012 at Ptc Therapeutics.
In the past five years, Preferred Stock Liabilities ranged from a high of $80.8 million in Q4 2012 to a low of $80.8 million in Q4 2012.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Stock Liabilities (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Ptc Therapeutics	6.51 Bn	4.61 Bn	244.52 Mn	-

Download Data

Date	Value
Dec 31, 2012	80.82 Mn